4.7
[1]. Caligiuri A, et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology. 2 Feb;124(2):54-2.
[2]. Erbler HC, et al. Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats. Acta Endocrinol (Copenh). 17 Jan;(1):147-56.
[]. Erbler HC, et al. On the mechanism of the inhibitory action of the spirolactone SC 76 (aldadiene) on the production of corticosteroids in rat adrenals in vitro. Naunyn Schmiedebergs Arch Pharmacol. 17;277(2):1-4.
[4]. Amitava Dasgupta, et al. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay. J Clin Lab Anal. 212 May;26():14-7.
[5]. Amitava Dasgupta, et al. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay. Ther Drug Monit. 28 Dec;(6):744-7.
H51-H411
P27-P28-P1-P45-P51
GHS8,GHS
77